United States Biotechnology & Medical Research

Sierra Oncology Inc (SRRA)

Track

Ticker: SRRA Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Sierra Oncology Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Planned sale 6 Apr 2022
Value US$191,321.71 | Price 202.09 | Shares 94,849 (-47.9%)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2022-04-07 2022-04-06 PlS Planned sale
3.0
Turner William D.

Chief Reg & Tech Ops Officer

Officer
94,849 -47.9%
202.09
US$191,322 		94,849 -47.9% 202.09 US$191,322
2022-04-07 2022-04-05 PlS Planned sale
3.0
Turner William D.

Chief Reg & Tech Ops Officer

Officer
65,851 -40.0%
308.09
US$3,554,653 		65,851 -40.0% 308.09 US$3,554,653
2022-04-04 2022-04-04 PlS Planned sale
Thomson Mary Christina

General Counsel, CCO & Sec'y

Officer
32,399 -23.9%
123.96
US$948,251 		32,399 -23.9% 123.96 US$948,251
2022-03-22 2022-03-18 PlS Planned sale
3.0
Turner William D.

Chief Reg & Tech Ops Officer

Officer
100 -100.0%
37.05
US$3,705 		100 -100.0% 37.05 US$3,705
2022-03-17 2022-03-17 PlS Planned sale
3.0
Turner William D.

Chief Reg & Tech Ops Officer

Officer
3,453 -100.0%
37.06
US$127,954 		3,453 -100.0% 37.06 US$127,954
2022-03-04 2022-03-04 PlS Planned sale
Thomson Mary Christina

General Counsel, CCO & Sec'y

Officer
2,000 -100.0%
30.60
US$61,196 		2,000 -100.0% 30.60 US$61,196
2022-02-08 2022-02-07 PlS Planned sale
3.0
Turner William D.

Chief Reg & Tech Ops Officer

Officer
10,000 -100.0%
32.32
US$323,225 		10,000 -100.0% 32.32 US$323,225
2022-02-04 2022-02-04 PlS Planned sale
Thomson Mary Christina

General Counsel, CCO & Sec'y

Officer
2,000 -100.0%
29.78
US$59,560 		2,000 -100.0% 29.78 US$59,560
2022-02-02 2022-02-02 B Purchase
2.9
Longitude Capital Partners III, LLC
Large shareholder
175,000 +inf%
27.00
US$4,725,000 		175,000 +inf% 27.00 US$4,725,000
2022-02-02 2022-02-02 B Purchase
Richardson Joshua
Non-Executive Director Large shareholder
175,000 +inf%
27.00
US$4,725,000 		175,000 +inf% 27.00 US$4,725,000
2022-02-01 2022-01-31 B Purchase
3.4
Sinclair Andrew
Non-Executive Director
150,000 +12.9%
27.00
US$4,050,000 		150,000 +12.9% 27.00 US$4,050,000
2022-02-01 2022-01-31 B Purchase
1.8
Abingworth LLP
Large shareholder
150,000 +12.9%
27.00
US$4,050,000 		150,000 +12.9% 27.00 US$4,050,000
2022-01-31 2022-01-31 B Purchase
3.4
Aggarwal Gaurav
Non-Executive Director Large shareholder
800,000 +41.3%
27.00
US$21,600,000 		800,000 +41.3% 27.00 US$21,600,000
2022-01-31 2022-01-31 B Purchase
2.9
Vivo Opportunity, LLC
Large shareholder
800,000 +41.3%
27.00
US$21,600,000 		800,000 +41.3% 27.00 US$21,600,000
2022-01-28 2022-01-26 PlS Planned sale
3.0
Turner William D.

Chief Reg & Tech Ops Officer

Officer
5,000 -100.0%
27.05
US$135,250 		5,000 -100.0% 27.05 US$135,250
2022-01-28 2022-01-26 PlS Planned sale
Thomson Mary Christina

General Counsel & Secretary

Officer
2,000 -100.0%
29.00
US$58,000 		2,000 -100.0% 29.00 US$58,000
2021-11-24 2021-11-24 B Purchase
3.7
Collard Craig A
Non-Executive Director
7,899 +141.0%
23.09
US$182,348 		7,899 +141.0% 23.09 US$182,348
2021-11-24 2021-11-23 B Purchase
3.7
Collard Craig A
Non-Executive Director
5,601 +inf%
22.95
US$128,515 		5,601 +inf% 22.95 US$128,515
2021-05-20 2021-05-19 B Purchase
4.1
DILLY STEPHEN GEORGE

CEO and President

Executive Director
5,000 +inf%
17.83
US$89,150 		5,000 +inf% 17.83 US$89,150
2020-08-18 2020-08-18 B Purchase
2.7
Klencke Barbara

Chief Development Officer

Officer
3,325 +198.5%
12.25
US$40,738 		3,325 +198.5% 12.25 US$40,738
2020-08-18 2020-08-18 B Purchase
2.7
Klencke Barbara

Chief Development Officer

Officer
5,950 +146.9%
12.22
US$72,710 		5,950 +146.9% 12.22 US$72,710
2019-08-26 2019-08-23 B Purchase Klencke Barbara

Chief Development Officer

Officer
108,000 +200.0%
0.44
US$47,380 		108,000 +200.0% 0.44 US$47,380
2019-08-26 2019-08-22 B Purchase Klencke Barbara

Chief Development Officer

Officer
54,000 +inf%
0.45
US$24,295 		54,000 +inf% 0.45 US$24,295
2019-08-26 2019-08-22 B Purchase Klencke Barbara

Chief Development Officer

Officer
67,000 +inf%
0.43
US$28,964 		67,000 +inf% 0.43 US$28,964
2018-12-11 2018-12-10 B Purchase Allen Andrew R Non-Executive Director
66,000 +inf%
1.64
US$108,240 		66,000 +inf% 1.64 US$108,240
2017-03-09 2017-03-08 B Purchase You Angie

Chief Bus. & Strat. Officer
30,000 +29.1%
1.43
US$42,900 		30,000 +29.1% 1.43 US$42,900
2017-02-16 2017-02-14 B Purchase Topper James N Large shareholder
5,925,926 +inf%
1.35
US$8,000,000 		5,925,926 +inf% 1.35 US$8,000,000
2016-03-24 2016-03-22 PlS Planned sale Chapman Wendy

SVP Clinical Operations

Officer
3,000 -100.0%
7.01
US$21,023 		3,000 -100.0% 7.01 US$21,023
2016-02-24 2016-02-22 PlS Planned sale Chapman Wendy

SVP Clinical Operations

Officer
3,000 -100.0%
7.06
US$21,180 		3,000 -100.0% 7.06 US$21,180
2016-01-25 2016-01-22 PlS Planned sale Chapman Wendy

SVP Clinical Operations

Officer
5,000 -100.0%
9.39
US$46,973 		5,000 -100.0% 9.39 US$46,973
2016-01-22 2016-01-22 PlS Planned sale Rodigueza Wendi

Chief Scientific Officer

Officer
1,000 -0.6%
9.66
US$9,660 		1,000 -0.6% 9.66 US$9,660
2016-01-22 2016-01-21 PlS Planned sale Rodigueza Wendi

Chief Scientific Officer

Officer
1,000 -0.6%
10.32
US$10,323 		1,000 -0.6% 10.32 US$10,323
2016-01-22 2016-01-20 PlS Planned sale Rodigueza Wendi

Chief Scientific Officer

Officer
1,000 -0.6%
9.59
US$9,590 		1,000 -0.6% 9.59 US$9,590
2016-01-19 2016-01-15 PlS Planned sale Glover Nicholas

CEO and President

Executive Director
5,000 -100.0%
10.04
US$50,223 		5,000 -100.0% 10.04 US$50,223
2016-01-14 2016-01-12 PlS Planned sale Lovejoy Chandra D

SVP of Reg. Affairs & Quality

Officer
5,562 -100.0%
11.93
US$66,345 		5,562 -100.0% 11.93 US$66,345
2016-01-14 2016-01-12 PlS Planned sale Lovejoy Chandra D

SVP of Reg. Affairs & Quality

Officer
15,411 -73.5%
11.06
US$170,489 		15,411 -73.5% 11.06 US$170,489
2015-07-21 2015-07-21 B Purchase CHA ALBERT Non-Executive Director
4,693 +0.2%
17.00
US$79,781 		4,693 +0.2% 17.00 US$79,781
2015-07-21 2015-07-21 B Purchase CHA ALBERT Non-Executive Director
215,307 +9.7%
17.00
US$3,660,219 		215,307 +9.7% 17.00 US$3,660,219
2015-07-21 2015-07-21 B Purchase ORBIMED ADVISORS LLC Non-Executive Director
175,000 +9.6%
17.00
US$2,975,000 		175,000 +9.6% 17.00 US$2,975,000
2015-07-21 2015-07-21 B Purchase Topper James N Non-Executive Director
220,000 +11.2%
17.00
US$3,740,000 		220,000 +11.2% 17.00 US$3,740,000
2015-07-21 2015-07-21 B Purchase VIVO VENTURES VII, LLC

Former 10% holder
4,693 +0.2%
17.00
US$79,781 		4,693 +0.2% 17.00 US$79,781
2015-07-21 2015-07-21 B Purchase VIVO VENTURES VII, LLC

Former 10% holder
215,307 +9.7%
17.00
US$3,660,219 		215,307 +9.7% 17.00 US$3,660,219
2015-07-21 2015-07-21 B Purchase Thompson Peter A. Non-Executive Director
175,000 +9.6%
17.00
US$2,975,000 		175,000 +9.6% 17.00 US$2,975,000
Explore more

More insider trading research around Sierra Oncology Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America